MSN Labs ramping up Favipiravir capacity

Hyderabad: With the spike Covid-19 cases resulting in shortage of anti-viral drugs, Hyderabad-based

MSN Labs

on Wednesday said it is not just ramping up capacities of Favipiravir but has also rolled out an affordable 800mg strength Favipiravir tablet for patient convenience.

MSN group executive director Bharat Reddy said the company is ramping up capacities from the existing over 1 lakh dosage regimen per day, which translates into 5 lakh strips of different strengths of its brand Favilow, up to 6-8 lakh dosage regimen per day (around 30 lakh strips) by next month.

For adults, the government has recommended a Favipiravir dosage of 1800 mg orally twice on the first day followed by 800 mg orally twice daily, up to a maximum of 14 days The capacity ramp-up will happen at its API and finished formulations facilities in Hyderabad, he said.

MSN, which had launched the world’s most affordable generic Favipiravir 200mg at Rs 33 per tablet under the Favilow brand in August last year, has rolled out the 800mg version of Favipiravir at Rs 144 per tablet.

“In the light of increasing Covid-19 cases in India, affordable treatment options are the need of the hour to flatten the curve. We are sure that our Favilow 800 would help support the nation’s efforts in overcoming the Covid crisis,” said MSN Group CMD MSN Reddy.